原发性输尿管癌31例临床分析

目的：提高原发性输尿管癌的术前诊断水平。方法：对南京医科大学第一附属医院1989-2002年间收治的31例原发性输尿管癌的临床资料进行回顾性分析。结果：31例中，肉眼血尿22例(71．0％)，腰痛11例(35，5％)。B超、静脉肾盂造影(IVU)、CT和逆行造影检查的阳性率分别为输尿管腔内占位4例(13．0％)、输尿管腔内占位3例(11．5％)、膀胱或合并膀胱占位8例(36．4％)，输尿管充盈缺损6例(40．0％)。29例患者经手术治疗，其中13例行患侧肾、输尿管、膀胱袖状切除。结论：老年患者反复发作的腰痛及血尿应考虑原发性输尿管癌的可能，造影诊断对本病有较高价值，应作CT及MRU无创检查。     

隐性脊柱裂排尿功能异常的临床特征

目的：研究伴有排尿功能障碍的隐性脊柱裂患者临床特征。方法：总结41例有明显排尿功能障碍的隐性脊柱裂患者临床资料。以18岁为界，将患者分为儿童组和成人组，所有患者均接受X线检查，除4例儿童外，均接受普通尿流动力学检查。结果：儿童组发病高峰年龄在1～2岁，主要临床表现为持续性原发性遗尿，部分伴有尿频、尿急及轻度急迫性尿失禁现象；成人组发病高峰年龄在18～26岁，主要临床表现为尿频、尿急、排尿前踌躇、排尿困难、遗尿等。结论：隐性脊柱裂患者常有排尿功能异常表现，出现症状的高峰时间为出生后及青春发育期后。X线、CT、MRI和尿流动力学等检查在隐性脊柱裂排尿功能障碍的诊断和治疗方案制定中有重要地位。     

Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes

Inactivated whole avian influenza virus (AIV) vaccine provides protection against homologous haemagglutinin (HA) subtype virus, but poor protection against a heterologous HA virus. Moreover, it induces chickens to produce antibodies to cross-reactive antigens, especially nucleoprotein, which is limits AIV serological surveillance. In this study, a recombinant fowlpox virus co-expressing HA (H5 subtype) and NA (N1 subtype) genes of AIV was evaluated for its ability to protect chickens against intramuscular challenge with a lethal dose of highly pathogenic (HP) AIV. Susceptible chickens were also vaccinated by wing-web puncture with the parent fowlpox vaccine virus. Following challenge 4 weeks later with HPAIV, all chickens vaccinated with recombinant virus were protected, while the chickens vaccinated with either the unaltered parent fowlpox vaccine virus or unvaccinated controls experienced 100% mortality following challenge. This protection was accompanied by the high levels of specific antibody to the respective components of the recombinant vaccine. The above results showed that rFPV-HA-NA could be a potential vaccine to replace current inactivated vaccines for preventing AI.     

化学振荡技术在中药研究中的应用

中药是一个多组分的复杂体系,质量监控因多方面因素较难实现,虽已有高效液相色谱等多种分析方法,但仍不十分理想,因此,有不少学者针对中药特性开展了多方面研究,力求开发一种既简便,又快捷,且能反映中药特性的分析方法。探讨采用电化学手段和振荡技术,获取中药及其制剂的特征振荡指纹图谱,依据图谱所反映的信息,确定中药种类及有关成分的量;通过15种草药和六味地黄中成药的振荡图谱,探讨了建立中药特征振荡图谱的理论,并进行了反应机制研究;介绍了中药特征振荡指纹图谱的研究方案及拟解决的关键问题;讨论了振荡体系对中药振荡图谱的影响,给出了中药振荡反应振荡系数的研究方法,基于图谱进行了动力学和反应机制研究。这种方法克服了中药化学成分复杂,相互干扰严重,难以确认的弊端,是一种新的研究手段。     

家用增压泵在进口中药液体包装机中的应用

本文介绍一种用国产热水增压泵替代进口中药包装机加压泵的方法.     

LONG-TERM OUABAIN ADMINISTRATION DOES NOT ALTER BLOOD PRESSURE IN CONSCIOUS SPRAGUE-DAWLEY RATS

1. We tested the ability of ouabain to cause chronic hyper tension by continuously infusing ouabain for 28 days (mini-osmotic pump implantation; i.p.). The blood pressure and metabolic effects of sham (150 mmol/L NaCI; n= 12) or ouabain infusion (10 μg/kg per day; n= 14; 100 μg/kg per day; n = 14) were examined in conscious Sprague-Dawley rats. 2. Plasma ouabain concentrations measured after 28 days of ouabain infusion were as follows: sham, not detectable (n= 11); ouabain 10 μg/kg per day, 0.60 ± 0.07 nmol/L (n= 14); and ouabain 100 μg/kg per day, 7.17 ± 0.57 nmol/L (n= 14; P < 0.001). 3. Sham or ouabain infusion did not alter food intake, bodyweight, water intake or urine output in conscious rats. 4. Blood pressure was not altered by sham treatment. Ouabain at 10 μg/kg per day or 100 μg/kg per day did not produce consistent rises in blood pressure. Ouabain at 10 μg/kg per day increased blood pressure on treatment day 12 only (+ 6mmHg; P < 0.05), while at 100μg/kg per day blood pres sure increased on treatment days 16 (+ 9 mmHg; P < 0.05) and day 18 (+ 8mmHg; P < 0.05) only. There was no significant difference in blood pressure between sham and ouabain groups. 5. Renal blood flow was decreased in rats infused with ouabain at 10 μg/kg per day (2.0 ± 0.3 mL/min per 100 g body-weight; n= 5; P < 0.01) and 100 μg/kg per day (2.2 ± 0.4 mL/ min per 100 g bodyweight; n= 7; P < 0.05) compared with sham treatment (3.5 ± 0.2 mL/min per 100 g bodyweight; n= 6). Renal vascular resistance was increased in rats treated with ouabain at 10 μg/kg per day (65.5 ± 12.6 mmHg/mL per min per 100 g bodyweight; n= 5; P < 0.01) and 100 μg/kg per day (66.0 ± 15.6 mmHg/mL per min per 100 g bodyweight; n= 7; P < 0.05) compared with sham treatment (32.6 ± 2.5 mmHg/mL per min per 100 g bodyweight; n= 6). 6. High plasma concentrations of ouabain do not cause consistent increases in blood pressure in conscious Sprague-Dawley rats.     

米非司酮作用于兔输卵管收缩活动与Ca^2＋关系的研究

通过“结合化学分离与原子吸收分光光度法”对Ca^2 含量测定和离体输卵管肌条收缩记录方法，研究米非司酮（Ru486)对增加假孕（4d)兔输卵管平滑肌收缩频率，而不改变其收缩张力和振幅时与Ca^2 之间的关系，结果提示：（1）Ru486对输卵管分泌液和组织内Ca^2 的含量分布无明显影响；（2）Ru486具有降低细胞外液高Ca^2 浓度促Ca^2 内流，而使收缩增强的效应，且能协同Ca^2 通道阻断剂（Verapamil)抑制细胞外Ca^2 内流，而致收缩减弱的效应。     

米非司酮对人子宫内膜癌HHUA细胞ER、PR及亚型体外作用的研究

目的　探讨抗孕激素米非司酮体外对人子宫内膜癌HHU A细胞ER、PR及亚型的影响及其与抗肿瘤作用的相关性。方法　体外培养子宫内膜癌HHU A细胞,不同浓度米非司酮处理细胞4 8小时,采用逆转录-聚合酶链反应(RT- PCR)半定量法检测PR- A m RNA,PR- B m RNA的表达水平;应用免疫组化法检测HHU A细胞ER、PR受体蛋白的表达变化。结果　米非司酮(5 μmol/ L)显著地降低HHU A细胞PR- B m RNA和PR受体蛋白的表达水平(P<0 .0 5 ) ,但增加米非司酮剂量并不能增强其降调作用。抗孕激素米非司酮对HHU A细胞PR- Am RNA和ER受体蛋白表达无明显影响(P>0 .0 5 )。结论　抗孕激素米非司酮可明显降调子宫内膜癌HHU A细胞PR- B m RNA水平和PR蛋白的表达,并与抑制癌细胞增殖密切相关     

提供系列人性化服务 促进产后母婴身心健康

目的为了增强产科在本县的竟争能力。方法2004年开始向产后母婴及母婴的监护人提供人性化系列服务。结果医院住院产妇人次及经济效益均得到很大的提高。讨论医护人员热情、主动、耐心、及时的服务,能使病人的心理、生理、自尊、被爱等需求得到满足,人性化产后母婴延伸系列服务,能满足很多不同层次人士的需要。     

3—氯—4—氟苯胺的生产与研究概况

评述了3-氯-4-氟苯胺的实验室研究和工业生产现状,特别对氯化、硝化、氟化和还原等反应中间体的制备及其质量作了分析。